BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib is a dual ABL-Src kinase inhibitor that exhibits a more potent but less selective inhibition of BCR-ABL than imatinib and is commonly used in treatment of imatinib resistant CML.